| Betty Hadji Momenian Dinarte, MD | |
|
6644 E Baywood Avenue, Mesa, AZ 85206 | |
| (480) 981-2000 | |
| Not Available |
| Full Name | Betty Hadji Momenian Dinarte |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 20 Years |
| Location | 6644 E Baywood Avenue, Mesa, Arizona |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538371752 | NPI | - | NPPES |
| MT184034 | Other | PA | MD LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | MT184034 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Suburban Hospital | Bethesda, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bethesda Emergency Associates, Llc | 4880581297 | 5 |
News Archive
ImmunoGen, Inc., a biopharmaceutical company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that Genentech, a member of the Roche Group, has disclosed that the U.S. Food and Drug Administration (FDA) has officially accepted the Biologics License Application (BLA) for trastuzumab emtansine and granted it Priority Review.
Ambry Genetics (Ambry), a leader in clinical genetic diagnostics and genetics software solutions, has announced new data affirming the effectiveness of multi-gene panel testing (MGPT) in identifying TP53 gene mutations in people who might otherwise not have been tested. The findings, presented as a poster at the American Society of Human Genetics (ASHG) 2015 Annual Meeting in Baltimore, includes data collected from more than 25,000 individuals having TP53 testing, of which 187 were positive. The tested cohort is the largest to date from a single testing laboratory.
In an analysis of data from several studies, watching television for 2-3 hours per day or more was associated with a higher risk of type 2 diabetes, fatal and nonfatal cardiovascular disease and all-cause death, according to a study in the June 15 issue of JAMA.
Cancer patients with brain metastases who develop blood clots may safely receive blood thinners without increased risk of dangerous bleeding, according to a study, published online today in Blood, the Journal of the American Society of Hematology.
New research led by Hana El-Samad of the University of California, San Francisco, and the Chan-Zuckerberg Biohub confirmed the beneficial use of an antiviral therapeutic called SARSNotch, which uses a combination of the SynNotch platform and de-novo designed protein binders. SARSNotch uses sentinel T cells to detect and mount a genetic response toward the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.
› Verified 1 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Mid-atlantic States,inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952461816 PECOS PAC ID: 3779495858 Enrollment ID: O20040105000308 |
News Archive
ImmunoGen, Inc., a biopharmaceutical company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that Genentech, a member of the Roche Group, has disclosed that the U.S. Food and Drug Administration (FDA) has officially accepted the Biologics License Application (BLA) for trastuzumab emtansine and granted it Priority Review.
Ambry Genetics (Ambry), a leader in clinical genetic diagnostics and genetics software solutions, has announced new data affirming the effectiveness of multi-gene panel testing (MGPT) in identifying TP53 gene mutations in people who might otherwise not have been tested. The findings, presented as a poster at the American Society of Human Genetics (ASHG) 2015 Annual Meeting in Baltimore, includes data collected from more than 25,000 individuals having TP53 testing, of which 187 were positive. The tested cohort is the largest to date from a single testing laboratory.
In an analysis of data from several studies, watching television for 2-3 hours per day or more was associated with a higher risk of type 2 diabetes, fatal and nonfatal cardiovascular disease and all-cause death, according to a study in the June 15 issue of JAMA.
Cancer patients with brain metastases who develop blood clots may safely receive blood thinners without increased risk of dangerous bleeding, according to a study, published online today in Blood, the Journal of the American Society of Hematology.
New research led by Hana El-Samad of the University of California, San Francisco, and the Chan-Zuckerberg Biohub confirmed the beneficial use of an antiviral therapeutic called SARSNotch, which uses a combination of the SynNotch platform and de-novo designed protein binders. SARSNotch uses sentinel T cells to detect and mount a genetic response toward the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.
› Verified 1 days ago
| Entity Name | Bethesda Emergency Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639125941 PECOS PAC ID: 4880581297 Enrollment ID: O20040301001187 |
News Archive
ImmunoGen, Inc., a biopharmaceutical company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that Genentech, a member of the Roche Group, has disclosed that the U.S. Food and Drug Administration (FDA) has officially accepted the Biologics License Application (BLA) for trastuzumab emtansine and granted it Priority Review.
Ambry Genetics (Ambry), a leader in clinical genetic diagnostics and genetics software solutions, has announced new data affirming the effectiveness of multi-gene panel testing (MGPT) in identifying TP53 gene mutations in people who might otherwise not have been tested. The findings, presented as a poster at the American Society of Human Genetics (ASHG) 2015 Annual Meeting in Baltimore, includes data collected from more than 25,000 individuals having TP53 testing, of which 187 were positive. The tested cohort is the largest to date from a single testing laboratory.
In an analysis of data from several studies, watching television for 2-3 hours per day or more was associated with a higher risk of type 2 diabetes, fatal and nonfatal cardiovascular disease and all-cause death, according to a study in the June 15 issue of JAMA.
Cancer patients with brain metastases who develop blood clots may safely receive blood thinners without increased risk of dangerous bleeding, according to a study, published online today in Blood, the Journal of the American Society of Hematology.
New research led by Hana El-Samad of the University of California, San Francisco, and the Chan-Zuckerberg Biohub confirmed the beneficial use of an antiviral therapeutic called SARSNotch, which uses a combination of the SynNotch platform and de-novo designed protein binders. SARSNotch uses sentinel T cells to detect and mount a genetic response toward the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Betty Hadji Momenian Dinarte, MD 24510 Burnt Hill Rd, Clarksburg, MD 20871-9236 Ph: (202) 679-7376 | Betty Hadji Momenian Dinarte, MD 6644 E Baywood Avenue, Mesa, AZ 85206 Ph: (480) 981-2000 |
News Archive
ImmunoGen, Inc., a biopharmaceutical company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that Genentech, a member of the Roche Group, has disclosed that the U.S. Food and Drug Administration (FDA) has officially accepted the Biologics License Application (BLA) for trastuzumab emtansine and granted it Priority Review.
Ambry Genetics (Ambry), a leader in clinical genetic diagnostics and genetics software solutions, has announced new data affirming the effectiveness of multi-gene panel testing (MGPT) in identifying TP53 gene mutations in people who might otherwise not have been tested. The findings, presented as a poster at the American Society of Human Genetics (ASHG) 2015 Annual Meeting in Baltimore, includes data collected from more than 25,000 individuals having TP53 testing, of which 187 were positive. The tested cohort is the largest to date from a single testing laboratory.
In an analysis of data from several studies, watching television for 2-3 hours per day or more was associated with a higher risk of type 2 diabetes, fatal and nonfatal cardiovascular disease and all-cause death, according to a study in the June 15 issue of JAMA.
Cancer patients with brain metastases who develop blood clots may safely receive blood thinners without increased risk of dangerous bleeding, according to a study, published online today in Blood, the Journal of the American Society of Hematology.
New research led by Hana El-Samad of the University of California, San Francisco, and the Chan-Zuckerberg Biohub confirmed the beneficial use of an antiviral therapeutic called SARSNotch, which uses a combination of the SynNotch platform and de-novo designed protein binders. SARSNotch uses sentinel T cells to detect and mount a genetic response toward the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.
› Verified 1 days ago
Dr. Ramona Beatrice Woodriffe, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 4824 E Baseline Rd, Suite 110, Mesa, AZ 85206 Phone: 480-969-4040 Fax: 480-830-1042 | |
David E. Boesch, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1010 N Country Club Dr, Banner Mesa Medical Center, Mesa, AZ 85201 Phone: 480-834-1211 | |
Charles H Pshaenich, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1400 S Dobson Rd, Mesa, AZ 85202 Phone: 480-456-9500 Fax: 480-820-7623 | |
Richard Scholl, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1840 S Stapley Dr, Suite 101, Mesa, AZ 85204 Phone: 480-206-2424 | |
Joseph W Winchell, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1400 S Dobson Rd, Mesa, AZ 85202 Phone: 480-456-9500 Fax: 480-820-7623 | |
Diane L. Elmore, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 450 N Dobson Rd Ste 108, Mesa, AZ 85201 Phone: 480-456-9300 | |
Dr. Drummond Grant Vogan, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 4850 E Baseline Rd Ste 107, Mesa, AZ 85206 Phone: 480-908-9892 Fax: 602-661-1189 |